EMA blesses ovarian cancer use for Roche's Avastin

Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report

Suggested Articles

Ibrance
Pharma

Pfizer's Ibrance flop shouldn't hurt metastatic sales: exec

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

by Carly Helfand
Bavencio
Pharma

Pfizer's Bavencio flops risky head and neck cancer trial

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

by Carly Helfand
Pharma

Astellas, SeaGen's' Padcev slashes bladder cancer risk by 30%

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

by Carly Helfand